ReviewDrugs2019
Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 199 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
199 citing papers in PubMed, 4 syntheses or guidelines pooled it, 317 citations in OpenAlex.
- Pooled it
- Prevalence and molecular characterization of ESBL-producing Enterobacteriaceae in Egypt: a systematic review and meta-analysis of hospital and community-acquired infections.Antimicrobial resistance and infection control · 2024Pooled it
- Predictors of mortality from extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia.Emerging microbes & infections · 2023Pooled it
- Pooled it
- Successful control of double carbapenemase-producingInfection prevention in practice · 2026Article
- Machine learning-based prediction of E. coli infection in hospitalized patients using a no-code analytical framework.Scientific reports · 2026Article
- Investigation of Biofilm Formation and Antimicrobial Resistance in Bacteria Isolated from Hospital Medical Devices.Microorganisms · 2026Article
- Nationwide spread of multidrug resistant Klebsiella pneumoniae across US communities.Nature communications · 2026Article
- Review
- In vitro activity of furazidin and comparator agents against bacterial isolates from urinary tract infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Emergence of multidrug-resistant and virulent Escherichia coli with APEC‑associated traits in broiler chickens from Ismailia, Egypt.Scientific reports · 2026Article
- Pathogenomics of multidrug-resistant Escherichia coli from bloodstream infections in South Africa.BMC medical genomics · 2026Article
- Transmission and Evolution of Antibiotic Resistance Genes and Antibiotic-Resistant Bacteria in Animals, Food, Humans and the Environment.Microorganisms · 2026Review
- Global resistome architecture of Escherichia coli across human and animal hosts: analysis of 9,696 genome.BMC microbiology · 2026Article
- Genomic epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Mwanza, Tanzania.Journal of global antimicrobial resistance · 2026Article
- Bloodstream Infections Due to Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2026Review
- Rapid commercial CTX-M diagnostics: Performance, limitations and clinical impact.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Article
- Contrasting pH optima of β-lactamases CTX-M and CMY influenceApplied and environmental microbiology · 2026Article
- Epidemiology of ESBL-Producing, Carbapenem-Resistant, and Carbapenemase-Producing Enterobacterales in Southern Africa.Antibiotics (Basel, Switzerland) · 2026Review
139 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are a major global public health concern. Presently, Escherichia coli with CTX-Ms are the most common species associated with global ESBLs; CTX-M-15 is the most frequent CTX-M worldwide and is followed by CTX-M-14, which is often found in South-East Asia. Recent surveillance studies showed that CTX-M-27 is emerging in certain parts of the world especially in Japan and Europe. The population structure of ESBL-producing E. coli is dominated globally by an high-risk clone named ST131. Escherichia coli ST131 belongs to three clades (A, B, and C) and three different subclades (C1, C1-M27, and C2). Clade C1-M27 is associated with bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.